Accuray (ARAY) Set to Announce Earnings on Wednesday

Accuray (NASDAQ:ARAY) is set to issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Accuray has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, January 31st. The medical equipment provider reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). Accuray had a negative return on equity of 28.11% and a negative net margin of 3.25%. The firm had revenue of $107.24 million for the quarter, compared to analysts’ expectations of $107.11 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Stock Performance

Shares of ARAY stock opened at $2.22 on Tuesday. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.84 and a current ratio of 1.58. Accuray has a fifty-two week low of $2.10 and a fifty-two week high of $4.30. The business has a fifty day simple moving average of $2.48 and a 200-day simple moving average of $2.63.

Analyst Ratings Changes

A number of brokerages recently commented on ARAY. Roth Mkm initiated coverage on shares of Accuray in a research note on Tuesday, February 13th. They issued a “buy” rating and a $9.00 price objective on the stock. Roth Capital reiterated a “buy” rating on shares of Accuray in a research report on Tuesday, February 13th. Finally, TheStreet cut shares of Accuray from a “c-” rating to a “d+” rating in a research note on Wednesday, February 14th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.25.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.